These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 12728284

  • 1. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
    Mease PJ.
    Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A, Esposito M, Costanzo A, Chimenti S.
    Am J Clin Dermatol; 2009 Jan; 10(5):319-24. PubMed ID: 19658444
    [Abstract] [Full Text] [Related]

  • 3. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F.
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [Abstract] [Full Text] [Related]

  • 4. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
    Krueger G, Callis K.
    Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
    [Abstract] [Full Text] [Related]

  • 5. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B, Sánchez-Carazo JL, Pérez-Ferriols A, Laguna C, Oliver V, Alegre V.
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [Abstract] [Full Text] [Related]

  • 6. Two years of experience with etanercept in recalcitrant psoriasis.
    Ahmad K, Rogers S.
    Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
    [Abstract] [Full Text] [Related]

  • 7. Etanercept (Enbrel) -- an update.
    Goffe B.
    Skin Therapy Lett; 2007 May; 9(10):1-4, 9. PubMed ID: 15657632
    [Abstract] [Full Text] [Related]

  • 8. Etanercept for psoriasis: two case reports.
    Fidalgo A, Baptista J, Rocha Páris F, Caldas Lopes L, Ferreira A.
    Int J Clin Pharmacol Res; 2005 May; 25(4):159-63. PubMed ID: 16402631
    [Abstract] [Full Text] [Related]

  • 9. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
    Strober BE, Clarke S.
    J Drugs Dermatol; 2004 May; 3(3):270-2. PubMed ID: 15176161
    [Abstract] [Full Text] [Related]

  • 10. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
    Pomerantz RG, Mody E, Husni ME, Qureshi AA.
    J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
    [Abstract] [Full Text] [Related]

  • 11. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
    de Vlam K, Lories RJ.
    Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
    [Abstract] [Full Text] [Related]

  • 12. Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study.
    Koc E, Tunca M, Akgul EO, Akar A, Kurt Y, Kurumlu Z, Erbil K, Kilic S.
    J Dermatol; 2009 Apr; 36(4):191-6. PubMed ID: 19348656
    [Abstract] [Full Text] [Related]

  • 13. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A, Etanercept Pediatric Psoriasis Study Group.
    N Engl J Med; 2008 Jan 17; 358(3):241-51. PubMed ID: 18199863
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
    Antoni C, Manger B.
    Z Rheumatol; 2003 Jun 17; 62(3):235-9. PubMed ID: 12827399
    [Abstract] [Full Text] [Related]

  • 15. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
    Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ.
    Lancet; 2000 Jul 29; 356(9227):385-90. PubMed ID: 10972371
    [Abstract] [Full Text] [Related]

  • 16. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.
    Health Technol Assess; 2006 Sep 29; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [Abstract] [Full Text] [Related]

  • 17. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, Reynolds A, Emery P.
    Rheumatology (Oxford); 2006 Aug 29; 45(8):1029-38. PubMed ID: 16782734
    [Abstract] [Full Text] [Related]

  • 18. Our experience with etanercept in the treatment of psoriasis.
    Kokelj F, Miertusova Tothova S, Patamia M, Trevisan G.
    Acta Dermatovenerol Croat; 2006 Aug 29; 14(4):241-5. PubMed ID: 17311738
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.